## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q86357

Tetsuro KIKUCHI, et al.

Appln. No.: 10/540,577 Group Art Unit: 1612

Confirmation No.: 6428 Examiner: Shelley R GRAHAM

Filed: June 24, 2005

For: CARBOSTYRIL DERIVATES AND SEROTONIN REUPTAKE INHIBITORS FOR

TREATMENT OF MOOD DISORDERS

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

## MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed (without a Statement Under 37 C.F.R § 1.97(e)) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/540,577

Attorney Docket No.: Q86357

Allowance, or an action that otherwise closes prosecution in the application (whichever is

earlier), and therefore the statutory fee of \$180.00 under 37 C.F.R. § 1.17(p) is being charged to

Deposit Account No. 19-4880 via EFS Payment Screen.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

/Brett S. Sylvester/ Brett S. Sylvester

Registration No. 32,765

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 14, 2008

2